ARA-290 Nerve Damage and Repair neuropathy, Phoenix Arizona peptide therapy

ARA-290 (Cibinetide): An Investigational Peptide Targeting the Innate Repair Receptor

ARA-290, also known as cibinetide or pyroglutamate helix B surface peptide (pHBSP), is an 11-amino-acid synthetic peptide derived from a specific region of erythropoietin (EPO). Unlike native EPO or traditional erythropoiesis-stimulating agents, ARA-290 was engineered to separate tissue-protective effects from hematopoietic activity. This distinction has made it a subject of interest in research on neuropathy, inflammation resolution, and tissue repair.

Mechanism of Action

Erythropoietin exerts two distinct sets of effects through different receptor complexes. The classic EPO receptor homodimer drives red blood cell production. In contrast, the innate repair receptor (IRR)—a heteromer of the EPO receptor and the β-common receptor (CD131)—is upregulated at sites of injury or inflammation and mediates cytoprotection, anti-inflammatory signaling, and tissue repair.

ARA-290 selectively activates the IRR. Downstream effects reported in preclinical and clinical studies include reduced pro-inflammatory cytokines (such as TNF-α and IL-6), decreased oxidative stress and apoptosis, support for mitochondrial function, reduced fibrosis, and promotion of nerve fiber repair processes. The peptide has a short plasma half-life (roughly 2 minutes after intravenous administration and around 20 minutes after subcutaneous dosing), yet biological effects can persist longer because activation of the IRR initiates sustained intracellular signaling cascades.

Importantly, ARA-290 does not stimulate erythropoiesis or increase hematocrit in the doses studied, avoiding the thromboembolic risks associated with full EPO.

Clinical Evidence in Small Fiber Neuropathy

The strongest human data for ARA-290 come from Phase 2 trials in small fiber neuropathy (SFN), particularly sarcoidosis-associated SFN and diabetic neuropathy.

In patients with sarcoidosis and SFN symptoms, randomized, double-blind, placebo-controlled studies (including intravenous dosing three times weekly and daily subcutaneous regimens of 1–8 mg for 28 days) showed statistically significant improvements in neuropathic symptom scores (Small Fiber Neuropathy Screening List), quality-of-life measures (SF-36 pain and physical functioning domains), thermal sensory thresholds, and exercise capacity on the 6-minute walk test. Some trials also demonstrated increases in corneal nerve fiber density or area measured by in vivo corneal confocal microscopy—an objective structural marker suggesting possible small-fiber regeneration rather than purely symptomatic relief. Benefits in symptoms were observed to persist for weeks after dosing ended in some studies.

In a Phase 2 trial in type 2 diabetes patients with painful neuropathy, daily subcutaneous ARA-290 (4 mg for 28 days) improved neuropathic symptoms on the PainDetect questionnaire, reduced HbA1c, and favorably affected lipid parameters (cholesterol-to-HDL ratio and triglycerides). Patients with lower baseline corneal nerve fiber density showed increases after treatment, while the placebo group did not. Safety assessments identified no major concerns, and anti-ARA-290 antibodies were not detected.

These trials were relatively small and short-term. Larger confirmatory studies have not been completed to date.

Other Areas of Investigation

Preclinical and limited clinical work has explored additional potential applications:

Metabolic effects: Beyond the diabetes neuropathy trial, animal models (including Goto-Kakizaki rats) showed improved glucose tolerance and insulin secretion characteristics without changes in hematocrit.

Cardiovascular aging and inflammation: Chronic administration in aged rats reduced cardiac inflammation, fibrosis markers, and age-associated declines in heart function while attenuating frailty measures.

Kidney protection: Preclinical models of ischemia-reperfusion injury demonstrated improved glomerular filtration rate and reduced structural damage markers.

Other models: Benefits have been reported in experimental colitis, wound healing (including diabetic models), and ischemic stroke (neuroprotection via β-common receptor-dependent pathways).

These findings remain largely preclinical or exploratory.

Safety Profile

Across published Phase 2 trials, ARA-290 was generally well tolerated. No consistent increases in hematocrit, hemoglobin, or platelet activation were observed. Adverse event rates were comparable to placebo in most reports, with no major cardiovascular or laboratory safety signals attributed to the peptide in the short-term studies conducted. Long-term safety data in larger populations are lacking.

Current Status and Limitations

ARA-290 was developed by Araim Pharmaceuticals. Despite encouraging Phase 2 signals—particularly the combination of symptomatic improvement and structural nerve fiber changes in SFN—no Phase 3 programs appear to have been completed, and the peptide is not approved for any indication by major regulatory agencies. Availability is limited to research settings.

Key limitations of the existing evidence include small sample sizes, short treatment durations (typically 28 days), heterogeneity in dosing regimens and routes, and the absence of large, long-term, multi-center confirmatory trials. While corneal nerve fiber density improvements are intriguing as a potential disease-modifying signal, correlation with durable clinical outcomes requires further validation.

Broader Context

ARA-290 illustrates a pharmacological strategy focused on resolving inflammation and supporting endogenous repair pathways rather than broad immune suppression or symptomatic blockade alone. This approach aligns with growing interest in targeting the hallmarks of aging and chronic inflammatory conditions through tissue-protective mechanisms. However, enthusiasm must remain proportional to the data: promising Phase 2 results in niche neuropathy populations do not yet establish broad efficacy or safety for widespread use in regenerative or longevity medicine.

Further well-designed clinical trials will be necessary to determine whether selective IRR activation with agents like ARA-290 can deliver meaningful, durable benefits across neurological, metabolic, and age-related conditions.

Note: ARA-290 remains an investigational compound. This article summarizes publicly available scientific literature and does not constitute medical advice. Individuals interested in neuropathy or related conditions should consult qualified healthcare professionals and rely on approved therapies.